Altimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
Top-line data from Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) to be reported in Q2 ...